Skip to content
Calculator
Evidence: HighPeptideFDA ApprovedLipoglycopeptideSingle-dose antibioticHalf-life ~245 hours

Oritavancin

A single-infusion antibiotic for serious skin infections

Oritavancin is a lipoglycopeptide antibiotic that attacks Gram-positive bacteria in several ways at once and stays in the body for weeks. One 1,200 mg infusion treats an acute skin infection, but it interferes with blood-clotting tests for up to two days.

Manufacturer's recommended dosing (FDA label): 1,200 mg, Single dose, Intravenous Details ↓

Overview

What is it?

Oritavancin binds the cell-wall precursor that vancomycin targets, binds a second site in the peptidoglycan bridge, and disrupts the bacterial membrane. That multiple attack gives rapid, concentration-dependent killing, and a terminal half-life of about 245 hours means a single dose covers the whole course of a skin infection.

In SOLO I, 954 patients received a single oritavancin dose or 7 to 10 days of vancomycin: the primary endpoint was met by 82.3% against 78.9%, within the noninferiority margin, with similar results for MRSA. SOLO II repeated the result in 1,005 patients (80.1% against 82.9%). Pooled safety across 976 oritavancin and 983 vancomycin patients was similar.

The label's first warning is unusual: oritavancin interferes with laboratory clotting tests, falsely prolonging them for up to 48 hours, and it may increase bleeding risk with warfarin. It is not for osteomyelitis, where more cases occurred in the oritavancin arm of the trials. Reports to FDA have since added signals not on the label, including anaphylaxis and breathlessness, though such reports cannot give rates.

The two oritavancin products are not prepared the same way. Orbactiv is given as 1,200 mg over three hours; Kimyrsa is 1,200 mg over one hour, and its label states the two differ in dose strength, infusion duration and preparation, including which diluents are compatible, and that each product's own instructions must be followed. Confusing them is a dispensing hazard rather than a theoretical one.

Its long half-life is the reason clinicians use it beyond the label, to finish courses without a line. After standard therapy for bloodstream infections, 90-day failure was 14% in a 72-patient series; in heart-pump driveline infections, a couple of doses shortened therapy by about three weeks; for bone infections, pooled observational data report about 81% success and a matched comparison found it similar to dalbavancin. None of this is randomised, and a review now proposes targets for monitoring blood levels when it is given repeatedly.

Endocarditis is the boldest off-label use. In a Spanish and Italian series of 27 patients, clinical success was 100% in complicated bloodstream infection and 86% in endocarditis; a smaller series using it to consolidate or suppress endocarditis and device infections succeeded in six of nine. Repeated doses accumulate: a 2026 pharmacokinetic model found exposure rising 1.9- to 3.5-fold depending on the dosing interval, which is why monitoring is proposed. A systematic review of 25 studies sums it up as effective for skin infection and promising, but unproven, elsewhere.

1 dose
Whole course for skin infection
SOLO I and II · Kimyrsa label
1,200 mg
Single dose, either product
Orbactiv 3 h, Kimyrsa 1 h · PMID 42500354
~245 h
Terminal half-life
Orbactiv label 12.3
Science

Mechanism of Action

Oritavancin is a lipoglycopeptide that attacks the bacterial cell wall at two sites and disrupts the membrane, with a half-life long enough for a single-dose course.

🧱

Cell-wall precursor

Binds the D-Ala-D-Ala end of cell-wall precursors, as vancomycin does.

🔗

Peptidoglycan bridge

Also binds the pentaglycyl bridge, a second site that vancomycin does not use.

💥

Membrane disruption

Its lipophilic side chain disrupts the bacterial membrane, giving rapid, concentration-dependent killing.

Evidence

Published Research

The studies behind oritavancin, from their PubMed abstracts.

Human2014

SOLO I: one dose against 7 to 10 days of vancomycin

In 954 patients, all three efficacy endpoints met the 10-point noninferiority margin: the primary endpoint 82.3% against 78.9%, investigator-assessed cure 79.6% against 80.0%, and lesion reduction 86.9% against 82.9%, with similar results by pathogen including MRSA.

PMID: 24897083
Human2015

SOLO II

In 1,005 patients, the primary composite endpoint was 80.1% on oritavancin and 82.9% on vancomycin, investigator-assessed cure 82.7% against 80.5% and lesion reduction 85.9% against 85.3%, all within the noninferiority margin, with similar adverse-event rates.

PMID: 25294250
Human2018

Pooled safety from both trials

Across 976 oritavancin-treated and 983 vancomycin-treated patients, the incidences of adverse events, serious adverse events and discontinuations were compared, supporting the single-dose regimen's tolerability.

PMID: 29358292
Human2024

Against dalbavancin, matched

In 131 propensity-matched pairs, mostly with osteomyelitis, clinical success at 90 days was 76% on multi-dose oritavancin and 79% on dalbavancin; adverse reactions trended higher on oritavancin (7% against 2%).

PMID: 38570019
Human2026

FDA adverse-event reports

Among 1,088 FDA adverse-event reports naming oritavancin as the primary suspect, chills was the strongest known signal; anaphylaxis, breathlessness, chest discomfort and throat tightness emerged as signals not in the label. Spontaneous reports cannot give rates.

PMID: 42609687
Human2024

Finishing bloodstream infection treatment

In 72 patients with Gram-positive bloodstream infection, mostly S. aureus, given oritavancin after a median 11 days of standard antibiotics, 14% met the composite failure endpoint at 90 days; 4% had kidney injury and 3% infusion reactions.

PMID: 38267844
Human2025

Heart-pump driveline infections

In 9 patients with 10 left ventricular assist device infection episodes, a median of 2 oritavancin doses after standard therapy achieved the primary endpoint in 90% and shortened therapy by a median 24 days; two had serious adverse events (delirium, shivers).

PMID: 41120906
Human2026

ORIBAC: bloodstream infection and endocarditis

In 27 patients in Spain and Italy, clinical success was 100% in complicated bloodstream infections and 85.7% in infective endocarditis, with two adverse events. It was retrospective and uncontrolled.

PMID: 41764708
Human2026

Consolidation or suppression in endocarditis

In 9 patients given repeated 1,200 mg doses about every 10 days, clinical success was 67%; both microbiological failures were heart-pump infections, and drug levels varied widely and sometimes accumulated.

PMID: 42500354
Human2026

Redosing by pharmacokinetic model

From 249 samples in 23 patients, some treated for up to 14 months, a model predicted accumulation of 3.5-fold with weekly and 1.9-fold with four-weekly dosing; a single 24-hour level predicted exposure well.

PMID: 42526659
Review2026

On-label and off-label use reviewed

Across 25 studies, cure in skin-infection trials was 79.6% to 83.3%, similar to vancomycin, and success in off-label studies ranged from 70% to 100%; the authors call for prospective trials and standard dosing.

PMID: 41891114
Review2025

Osteomyelitis: observational studies pooled

Across nine observational studies of 316 patients with osteomyelitis, pooled clinical success was 81%. Osteomyelitis is not a labelled use, and no randomised trial exists.

PMID: 41224240
Review2026

Targets for drug monitoring

A systematic review of nine studies found strongly concentration-dependent killing in the laboratory and animals, and in the one repeated-dose human study time above the MIC predicted success; the authors propose targets for therapeutic monitoring.

PMID: 41914554
Dosing

Dosing Data

Oritavancin is a single 1,200 mg intravenous dose for acute bacterial skin infections; the two products differ in infusion time and preparation.

Hospital or infusion-centre antibiotic; it falsely prolongs some clotting tests for up to 48 hours, and Orbactiv and Kimyrsa must not be prepared interchangeably.
ProtocolDoseFrequencyDurationRoute
Label: acute bacterial skin and skin structure infections (Orbactiv) Approved labelOrbactiv (oritavancin) for injection US prescribing information (DailyMed set ff09a726, effective September 15, 2026)1,200 mgSingle doseInfused over 3 hoursIntravenous
Label: acute bacterial skin and skin structure infections (Kimyrsa) Approved labelKimyrsa (oritavancin) for injection US prescribing information (DailyMed set 5e755c40, effective December 18, 2025)1,200 mgSingle doseInfused over 1 hourIntravenous

Educational information, not medical advice. Each dose above is tagged with its source: an approved label, a published human study, animal data, or amounts reported by users. None is a recommendation for you. An unapproved compound has no established safe or effective human dose, and products sold for “research use only” are not made or tested for people. Talk to a doctor before acting on anything on this site, including before you start, stop or change any medicine or dose. Full medical disclaimer.

One fixed dose
Oritavancin is a single 1,200 mg infusion prepared by the pharmacy following the specific product's instructions; there is no weight-based maths.
For Buyers

What a Buyer Needs to Know

What is sold, how it is mixed, stored and taken, and what is known about its safety, quality and legal status. Each part names its source. Where we have none, it says unknown.

What is sold

The approved product, as its label describes it:

Source: Orbactiv (oritavancin injection) label, section 3 (DailyMed version 14, effective September 15, 2026).

Mixing a vial: a worked example

Nothing to mix at home, and no syringe units to work out: Oritavancin is prepared and given by clinical staff, in hospital or an infusion centre.

Its US labels give it as one infusion into a vein, and only after the powder is dissolved and diluted.

Source: Orbactiv (oritavancin injection) label, section 2 (DailyMed version 14, effective September 15, 2026).

Storage before and after mixing

Before mixing or first use: “ORBACTIV vials should be stored at 20°C to 25°C (68°F to 77°F); excursions permitted to 15°C to 30°C (59°F to 86°F).”

After mixing or first use: “Storage and Use of Intravenous Solution: Diluted intravenous solution in an infusion bag should be used within 6 hours when stored at room temperature, or used within 12 hours when refrigerated at 2 to 8°C (36 to 46°F).” “The combined storage time (reconstituted solution in the vial and diluted solution in the bag) and 3 hour infusion time should not exceed 6 hours at room temperature or 12 hours if refrigerated.” “Discard any unused portion of the reconstituted solution remaining in each vial.”

Source: Orbactiv (oritavancin injection) label, sections 16 and 2 (DailyMed version 14, effective September 15, 2026).

How it is taken

As the approved label gives it: Intravenous (Single dose; Label: acute bacterial skin and skin structure infections (Orbactiv)).

Source: Manufacturer's recommended dosing (FDA label): the route and frequency of each row in Dosing Data below.

What to expect, and when

How long it stays in the body: a half-life of terminal half-life about 245 hours. After about five half-lives almost none is left.

How long the doses were given: Label: acute bacterial skin and skin structure infections (Orbactiv): Infused over 3 hours; Label: acute bacterial skin and skin structure infections (Kimyrsa): Infused over 1 hour.

When effects appear: unknown; no source on this page gives a time to effect for Oritavancin. Results reported in the studies are under Published Research.

Source: half-life: Orbactiv prescribing information, section 12.3 (DailyMed set ff09a726, effective September 15, 2026); Manufacturer's recommended dosing (FDA label), the duration of each row in Dosing Data below.

Side effects, and when to stop or get help

From the Side Effects section: Adverse-event rates similar to vancomycin across both phase 3 trials. Full list and cautions ↓

When to stop or get help: unknown; the label's warnings summary we read gives no rule for stopping Oritavancin. Treat a severe or unexpected reaction as a reason to stop and see a doctor.

Source: the Side Effects section below (“From the studies above”).

Interactions

  • drugs predominantly metabolised by CYP2C9, CYP2C19, CYP3A4 or CYP2D6: oritavancin is a weak nonspecific inhibitor or inducer of these enzymes; the label says to avoid co-administration or monitor for toxicity or lack of efficacy
  • warfarin: no effect on S-warfarin exposure in a study, but the label advises monitoring for bleeding
  • phospholipid-dependent clotting tests: artificially prolongs aPTT for up to 120 hours, PT and INR up to 12 hours, and other tests for up to 72 hours; a chromogenic factor Xa assay is unaffected
  • blood cross-matching: positive indirect and direct antiglobulin tests were seen, which may interfere with cross-matching before transfusion

Every peptide's record, with its source: the interaction matrix.

Source: Melinta. ORBACTIV (oritavancin) for injection, US prescribing information, section 7. DailyMed version effective September 15, 2026, read October 3, 2026.

Checking what you bought

Unknown: no published independent test of Oritavancin products is in our lab-results database yet, so how products sold under this name measure up is not known.

To read a certificate of analysis, paste it into the COA decoder. Trust & Verification explains what independent testing can and cannot show.

Legal status

US: FDA Approved (Approved in the US as Orbactiv (Melinta) for acute bacterial skin and skin structure infections in adults). Sport: Not on the 2026 List.

Country by country ↓ · Regulatory tracker

Source: this entry's approval status and the WADA Prohibited List, as in Legal Status below.

Safety

Side Effects & Contraindications

Reported Side Effects

From the studies above.

● Adverse-event rates similar to vancomycin across both phase 3 trials

Contraindications & Cautions

Warnings from the Orbactiv label (DailyMed, effective September 15, 2026).

● Interference with laboratory clotting tests
● Hypersensitivity and infusion-related reactions
● Clostridioides difficile-associated diarrhoea
● Potential bleeding risk with warfarin
● Osteomyelitis: more cases in the oritavancin arm of the trials
Questions

Frequently Asked Questions

?How many doses of oritavancin are needed?

One. A single 1,200 mg intravenous infusion treats an acute bacterial skin and skin structure infection, because the drug's terminal half-life is about 245 hours.

?Why does oritavancin affect blood tests?

It binds to reagents used in laboratory clotting tests, falsely prolonging results for up to 48 hours. Its label warns about this first, and about bleeding risk with warfarin.

?What is the difference between Orbactiv and Kimyrsa?

They are two oritavancin products that differ in dose strength, infusion duration and preparation instructions. The label says to follow each product's own instructions.

?Is oritavancin used for bone infection?

No. The Orbactiv label warns that more cases of osteomyelitis were reported in the oritavancin arm of its trials, and that patients with suspected or confirmed osteomyelitis should be treated according to standard of care.

Bibliography

References

  1. [fda] US FDA, Drugs@FDA (openFDA): KIMYRSA, NDA 214155 (March 12, 2021), a second oritavancin product. Read October 3, 2026.
  2. [fda-pi] FDA. Orbactiv (oritavancin) US prescribing information (DailyMed set ff09a726-9f9b-4e30-b509-396781293220, version 14, effective September 15, 2026). Read October 3, 2026.
  3. [clinical-trial] Corey GR, et al. "Single-dose oritavancin in the treatment of acute bacterial skin infections." N Engl J Med, 2014;370(23):2180-90. PMID: 24897083.
  4. [clinical-trial] Corey GR, et al. "Single-dose oritavancin versus 7-10 days of vancomycin in the treatment of gram-positive acute bacterial skin and skin structure infections: the SOLO II noninferiority study." Clin Infect Dis, 2015;60(2):254-62. PMID: 25294250.
  5. [pubmed] Corey GR, et al. "Single Intravenous Dose of Oritavancin for Treatment of Acute Skin and Skin Structure Infections Caused by Gram-Positive Bacteria: Summary of Safety Analysis from the Phase 3 SOLO Studies." Antimicrob Agents Chemother, 2018;62(4). PMID: 29358292.
  6. [pubmed] Krsak M, et al. "Oritavancin for Treatment of Osteomyelitis: A Systematic Review and Meta-Analysis of Observational Studies." Pharmacotherapy, 2025;45(11):754-763. PMID: 41224240.
  7. [pubmed] Steuber TD, et al. "Head-to-head comparison of multi-dose oritavancin and dalbavancin for complicated infections: A propensity score-matched analysis." Int J Antimicrob Agents, 2024;63(6):107165. PMID: 38570019.
  8. [pubmed] Xie B, et al. "Oritavancin safety: a real-world pharmacovigilance study of the FAERS database." Front Cell Infect Microbiol, 2026;16:1798934. PMID: 42609687.
  9. [pubmed] Texidor WM, et al. "Oritavancin as sequential therapy for Gram-positive bloodstream infections." BMC Infect Dis, 2024;24(1):127. PMID: 38267844.
  10. [pubmed] Załęska-Kocięcka M, et al. "Oritavancin in LVAD related infections - a chance for shortening therapy and improving outcomes." BMC Infect Dis, 2025;25(1):1358. PMID: 41120906.
  11. [pubmed] Baiardi G, et al. "Extrapolation of oritavancin PK/PD targets to inform therapeutic drug monitoring: a systematic review." J Antimicrob Chemother, 2026;81(4). PMID: 41914554.
  12. [fda-pi] Kimyrsa (oritavancin) for injection US prescribing information (DailyMed set 5e755c40, version 7, effective December 18, 2025), section 2; read through openFDA October 6, 2026.
  13. [pubmed] Vena A, et al. "Oritavancin in Complicated Bloodstream Infections and Endocarditis in Spain and Italy (ORIBAC Study): A Retrospective Multicenter Observational Study." Infect Dis Ther, 2026;15(4):1075-1092. PMID: 41764708.
  14. [pubmed] Giuliano S, et al. "Oritavancin as consolidation or suppressive therapy in infective endocarditis and device-related infections: real-world experience with therapeutic drug monitoring." JAC Antimicrob Resist, 2026;8(4):dlag150. PMID: 42500354.
  15. [pubmed] Giuliano S, et al. "Precision redosing of oritavancin: A population pharmacokinetic framework to optimize long-term therapy for complex gram-positive infections." Int J Antimicrob Agents, 2026;67(11):107943. PMID: 42526659.
  16. [pubmed] Soriano A, et al. "Evaluating oritavancin for Gram-positive infections: a systematic review of on-label and off-label use." Drugs Context, 2026;15. PMID: 41891114.

Sources & Citations

Studies were read from their PubMed abstracts; the Orbactiv label (read October 3, 2026) and the Kimyrsa label from DailyMed through openFDA (read October 6, 2026).

Medical Disclaimer: This content is for educational and informational purposes only. It is not medical advice, and nothing here is an instruction to obtain or use any compound. Talk to a licensed clinician about your own situation.

Last reviewed: 2026-10-03